Compare Davita Inc (DVA) vs Starbucks Corp (SBUX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Davita Inc vs Starbucks Corp — how do they compare? Davita Inc trades at $178.34 (market cap $11.72B), while Starbucks Corp trades at $106.56 (market cap $119.30B). The key difference: Starbucks Corp is far larger — about 10.2× Davita Inc's market cap, and Starbucks Corp pays a 2.37% dividend while Davita Inc pays none. Which is the better fit depends on your goals.
| DVA | SBUX | |
|---|---|---|
Market Cap | $11.72B | $119.30B |
Sector | Health | Consumer Cyclical |
52-Week High | $240.96 | $108.37 |
52-Week Low | $103.87 | $78.46 |
Enterprise Value | $24.44B | $138.12B |
Volume | — | 7,493,833 |
Dividend Yield | — | 2.37% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $183.77, up 1.72% today, with a mixed technical picture showing bearish moving averages but bullish oscillators. The company reported strong Q2 2026 earnings of $4.02 per share, beating estimates, driven by volume growth. Revenue reached $13.64 billion in 2025, with a net income margin of 6.05%. Analyst consensus is a Buy with a $232.25 price target, though technical signals are bearish overall.
The outlook for DVA is cautiously optimistic, supported by earnings beats and volume growth, but risks include reimbursement pressure and high debt levels. The stock offers potential upside to the consensus target, yet investors face headwinds from margin compression and technical bearishness.
Starbucks (SBUX) trades at $105.58, up 0.4% today, with a bullish technical signal and recent earnings beats driving momentum. The stock shows strong fundamental recovery with Q2 2026 EPS of $0.85 beating estimates by 29%, while revenue growth and margin expansion support a raised 2026 outlook. Analyst consensus is split evenly between Buy and Hold, with a $113.60 price target suggesting modest upside from current levels.
The outlook is positive as operational improvements and traffic recovery underpin earnings growth, but high valuation multiples (P/E 61) and competitive pressures pose risks. Investor sentiment is cautiously optimistic, focusing on sustained execution of the turnaround strategy amid macroeconomic uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Davita Inc
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →About Starbucks Corp
Starbucks Corporation retails, roasts, and provides its own brand of specialty coffee. The Company operates retail locations worldwide and sells whole bean coffees through its sales group, direct response business, supermarkets, and on the world wide web. Starbucks also produces and sells bottled coffee drinks and a line of ice creams.
Read more on SBUX →
